BioSurfaces
Ashland, US · Founded 2018 · Massachusetts LLC
BioSurfaces develops medical devices, 3D tissue engineering scaffolds, and personal care products using its proprietary Bio-Spun nanofiber technology. The company works in the medical device and tissue engineering space, with collaborations that include Takeda, NIH, and Corning.
BiotechMedical DevicesNew Materials
Founders & leadership
BioSurfaces was founded in 2018 by Tina M Phaneuf and Matthew D. Phaneuf.
TM
Tina M PhaneufExecutive Officer and Director of Manager
MD
Matthew D. PhaneufExecutive Officer and Director of Manager
Board
TL
Thomas L BarretteDirector of Manager
Reported raises · per SEC filings
Form D private placements$900K disclosed across 1 round · 2018
▶$900KraisedMar 2018 · 10 investors · BiotechnologyRule 506(b)
▶$900KraisedMar 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tina M PhaneufExecutive Officer, Director
- Matthew D. PhaneufExecutive Officer, Director
- Thomas L BarretteDirector
- Amount sold
- $900K
- Minimum investment
- $25K
- Proceeds to insiders
- $150K
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Massachusetts, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBiomerics9 shared keywordsBiomerics is a contract development and manufacturing organization (CDMO) that produces interventional medical device components, including plastic parts and micro metal components for OEMs. It serves markets such as medical robotics, cardiovascular, and endoscopy, with facilities in Costa Rica, the Dominican Republic, and other global medical device hubs.
Imbed Biosciences8 shared keywordsImbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.
Companies competing with BioSurfaces for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 16 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $884.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $275.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $988.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2011 | $749K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $111.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2009 | $110.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2008 | $100K |
| National Science Foundation | Phase ISTTR | 2007 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $744.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2006 | $744.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2005 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $200K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does BioSurfaces do?
- BioSurfaces develops medical devices, 3D tissue engineering scaffolds, and personal care products using its proprietary Bio-Spun nanofiber technology. The company works in the medical device and tissue engineering space, with collaborations that include Takeda, NIH, and Corning.
- Who founded BioSurfaces?
- BioSurfaces was founded by Tina M Phaneuf, Matthew D. Phaneuf in 2018.
- How much funding has BioSurfaces raised?
- BioSurfaces has disclosed $900K raised across 1 round.
- Where is BioSurfaces headquartered?
- BioSurfaces is headquartered in Ashland, US.